Durability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants
Amarendra Pegu(National Institutes of Health), Sarah O’Connell(National Institutes of Health), Stephen D. Schmidt(National Institutes of Health), Sijy O’Dell(National Institutes of Health), Chloe Adrienna Talana(National Institutes of Health), Lilin Lai(Emory University), Jim Albert(Emory University), Evan J. Anderson(Emory University), Hamilton Bennett(National Institutes of Health), Kizzmekia S. Corbett(National Institutes of Health), Britta Flach(National Institutes of Health), Lisa A. Jackson(Kaiser Permanente Washington Health Research Institute), Brett Leav(National Institutes of Health), Julie E. Ledgerwood(National Institutes of Health), Catherine J. Luke(National Institutes of Health), Mat Makowski(National Institutes of Health), Martha Nason(National Institutes of Health), Paul C. Roberts(National Institutes of Health), Mario Roederer(National Institutes of Health), Paulina A. Rebolledo(Emory University), Christina A. Rostad(National Institutes of Health), Nadine Rouphael(National Institutes of Health), Wei Shi(National Institutes of Health), Lingshu Wang(National Institutes of Health), Alicia T. Widge(National Institutes of Health), Eun Sung Yang(National Institutes of Health), The mRNA-1273 Study Group§(National Institutes of Health), John H. Beigel(National Institutes of Health), Barney S. Graham(National Institutes of Health), John R. Mascola(National Institutes of Health), Mehul S. Suthar(Emory University), Adrian B. McDermott(National Institutes of Health), Nicole A. Doria‐Rose(National Institutes of Health), Jae Arega, John H. Beigel(National Institutes of Health), Wendy Buchanan, Mohammed Elsafy, Binh Hoang, Rebecca Lampley(National Institutes of Health), Aparna Kolhekar, Hyung Il Koo, Catherine J. Luke(National Institutes of Health), Mamodikoe Makhene(National Institutes of Health), Seema Nayak, Rhonda Pikaart-Tautges, Paul C. Roberts(National Institutes of Health), Janie Russell, Elisa Sindall(Emmes (United States)), Jim Albert(Emory University), Pratap Kunwar, Mat Makowski(Emmes (United States)), Evan J. Anderson(Emory University), Amer Bechnak, Mary Bower(Emory University), Andrés Camacho-González, Matthew H. Collins, Ana Drobeniuc, Venkata Viswanadh Edara, Srilatha Edupuganti, Katharine Floyd, Theda Gibson, Cassie M. Grimsley Ackerley, Brandi Johnson, Satoshi Kamidani(Emory University), Carol Kao, Colleen F. Kelley, Lilin Lai(Emory University), Hollie Macenczak, Michele Paine McCullough(Emory University), Etza Peters(Emory University), Varun K. Phadke(National Institutes of Health), Paulina A. Rebolledo(Emory University), Christina A. Rostad(Emory University), Nadine Rouphael(Emory University), Erin M. Scherer, Amy C Sherman, Kathy Stephens, Mehul S. Suthar(Emory University), Mehgan Teherani, Jessica Traenkner, Juton R. Winston, İnci Yıldırım, Lee Barr, Joyce Benoit, Barbara Carste, Joe Choe, Maya Dunstan(Kaiser Permanente Washington Health Research Institute), Roxanne Erolin, Jana ffitch, Colin Fields, Lisa A. Jackson(Kaiser Permanente Washington Health Research Institute), Erika Kiniry, Susan Lasicka, Stella E. Lee, M. Nguyen(Moderna Therapeutics (United States)), Stephanie Pimienta, Janice Suyehira, Michael M. Witte, Hamilton Bennett(Moderna Therapeutics (United States)), Nedim Emil Altaras, Andrea Carfı́(National Institutes of Health), Marjorie Hurley(National Institutes of Health), Brett Leav(Moderna Therapeutics (United States)), Rolando Pajón, Wellington Sun, Tal Zaks, Rhea N. Coler, Sasha E. Larsen, Kathleen M. Neuzil, Lisa C. Lindesmith, David R. Martinez, Jennifer E. Munt, Michael L. Mallory, Caitlin E. Edwards, Ralph S. Baric(National Institutes of Health), Nina M. Berkowitz, Eli Boritz(National Institutes of Health), Kevin Carlton(National Institutes of Health), Kizzmekia S. Corbett(National Institutes of Health), Pamela Costner(National Institutes of Health), Adrian Creanga, Nicole A. Doria‐Rose(National Institutes of Health), Daniel C. Douek(National Institutes of Health), Britta Flach(National Institutes of Health), Martin R. Gaudinski(National Institutes of Health), Ingelise J. Gordon, Barney S. Graham(National Institutes of Health), LaSonji A. Holman, Julie E. Ledgerwood(National Institutes of Health), Kwanyee Leung(National Institutes of Health), Bob C. Lin, Mark K. Louder, John R. Mascola(National Institutes of Health), Adrian B. McDermott(National Institutes of Health), Kaitlyn M. Morabito, Laura Novik(National Institutes of Health), Sarah O’Connell(National Institutes of Health), Sijy O’Dell(National Institutes of Health), Marcelino Padilla, Amarendra Pegu(National Institutes of Health), Stephen D. Schmidt(National Institutes of Health), Wei Shi(National Institutes of Health), Phillip A. Swanson(National Institutes of Health), Chloe Adrienna Talana(National Institutes of Health), Lingshu Wang(National Institutes of Health), Alicia T. Widge(National Institutes of Health), Eun Sung Yang(National Institutes of Health), Yi Zhang(National Institutes of Health), James D. Chappell, Mark R. Denison, Tia M. Hughes, Xiaotao Lu, Andrea J. Pruijssers, Laura J. Stevens(National Institutes of Health), Christine M. Posavad, Michael Gale, Vineet D. Menachery, Pei‐Yong Shi
Cited by 597Open Access
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mutations may diminish vaccine-induced protective immune responses, particularly as antibody titers wane over time. Here, we assess the effect of SARS-CoV-2 variants B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma), B.1.429 (Epsilon), B.1.526 (Iota), and B.1.617.2 (Delta) on binding, neutralizing, and angiotensin-converting enzyme 2 (ACE2)–competing antibodies elicited by the messenger RNA (mRNA) vaccine mRNA-1273 over 7 months. Cross-reactive neutralizing responses were rare after a single dose. At the peak of response to the second vaccine dose, all individuals had responses to all variants. Binding and functional antibodies against variants persisted in most subjects, albeit at low levels, for 6 months after the primary series of the mRNA-1273 vaccine. Across all assays, B.1.351 had the lowest antibody recognition. These data complement ongoing studies to inform the potential need for additional boost vaccinations.
Related Papers
No related papers found
Powered by citation graph analysis